BVF Partners is a venture capital firm that invests in early stage startup companies.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
BVF Partners is a venture capital firm that invests in early stage startup companies.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2018 | Olema Oncology | Series A | 6.1M |
5/2020 | Surface Oncology | Post-IPO Equity | 28.9M |
3/2018 | Prevail Therapeutics | Series A | 75M |
11/2014 | GTx | Post-IPO Equity | 43.4M |
9/2017 | Realm Therapeutics | Post-IPO Equity | 26M |
5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
7/2017 | BiolineRx | Post-IPO Equity | 9.6M |
1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
7/2019 | Revolution Medicines | Series C | 100M |
11/2017 | Arcus Biosciences | Series C | 107M |
5/2013 | Cascadian Therapeutics | Post-IPO Equity | 10M |
3/2018 | IDEAYA Biosciences | Series B | 0 |
9/2010 | Addex Therapeutics | Post-IPO Equity | 19.9M |
1/2003 | Biotica Technology | Series A | 5M |
8/2013 | Addex Therapeutics | Post-IPO Equity | 3.5M |
5/2018 | MEI Pharma | Post-IPO Equity | 75M |
4/2021 | Ventus Therapeutics | Series B | 100M |
6/2020 | Autobahn Therapeutics | Series B | 76M |
6/2016 | Pieris Pharmaceuticals | Post-IPO Equity | 16.5M |
3/2021 | Pyxis Oncology | Series B | 152M |
7/2020 | Olema Oncology | Series B | 54M |
4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
9/2022 | Nimbus Therapeutics | Venture Round | 0 |
1/2014 | Blueprint Medicines | Series B | 25M |
12/2018 | Akero Therapeutics | Series B | 70M |
5/2018 | Rain Therapeutics | Series A | 18.4M |
1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
9/2013 | Evotec | Venture Round | 40M |
3/2015 | Tobira Therapeutics | Convertible Note | 13M |
11/2001 | Phylogix Inc. | Series A | 3M |
8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
3/2018 | ViewPoint Therapeutics | Series B | 0 |
3/2004 | Phylogix Inc. | Series B | 12M |
8/2017 | Molecular Templates | Post-IPO Equity | 60M |
3/2019 | Prevail Therapeutics | Series B | 50M |
9/2018 | 4D Molecular Therapeutics | Series B | 0 |
2/2018 | Merus | Post-IPO Equity | 55.8M |
2/2019 | Peloton Therapeutics | Series E | 0 |
11/2014 | Ziarco | Series B | 33M |
7/2015 | AnaptysBio | Series D | 40M |
12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
12/2017 | Relay Therapeutics | Series B | 63M |
3/2020 | Kymera Therapeutics | Series C | 102M |
4/2019 | Vividion Therapeutics | Series B | 82M |
12/2018 | Relay Therapeutics | Series C | 0 |
7/2021 | Nimbus Therapeutics | Venture Round | 0 |
4/2021 | Ventus Therapeutics | Series B | 0 |
3/2021 | Pyxis Oncology | Series B | 0 |
12/2020 | Gritstone Bio | Post-IPO Equity | 0 |
7/2020 | Olema Oncology | Series B | 0 |
6/2020 | Autobahn Therapeutics | Series B | 0 |
5/2020 | Surface Oncology | Post-IPO Equity | 0 |
3/2020 | Kymera Therapeutics | Series C | 0 |
1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
7/2019 | Revolution Medicines | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|